These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 38114801

  • 1. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow CJ, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC.
    J Neurooncol; 2024 Jan; 166(1):73-78. PubMed ID: 38114801
    [Abstract] [Full Text] [Related]

  • 2. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow C, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC.
    Res Sq; 2023 Oct 06. PubMed ID: 37886555
    [Abstract] [Full Text] [Related]

  • 3. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
    JAMA Oncol; 2023 Jul 01; 9(7):919-927. PubMed ID: 37200021
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.
    Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, Wang Y.
    Cancer Biol Med; 2021 Feb 15; 18(1):272-282. PubMed ID: 33628600
    [Abstract] [Full Text] [Related]

  • 5. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
    Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ.
    Clin Cancer Res; 2022 Jun 13; 28(12):2527-2535. PubMed ID: 35275197
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W, Thong E, Andrabi S, Verma V, Brian Butler E, Teh BS.
    J Clin Neurosci; 2021 Mar 17; 85():115-121. PubMed ID: 33581781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
    Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.
    JAMA Oncol; 2018 Oct 01; 4(10):1405-1409. PubMed ID: 29955793
    [Abstract] [Full Text] [Related]

  • 16. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 17. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL, Lee L, See AAQ, Ang TY, Ang BT, King NKK.
    BMC Cancer; 2020 Jan 31; 20(1):79. PubMed ID: 32005184
    [Abstract] [Full Text] [Related]

  • 18. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H, Li J, Cheng G, Zhang J, Li X.
    Clin Neurol Neurosurg; 2016 Dec 31; 151():31-36. PubMed ID: 27764705
    [Abstract] [Full Text] [Related]

  • 19. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
    Kong DS, Kim HR, Choi YR, Seol HJ, Lee JI, Nam DH.
    J Clin Neurosci; 2015 Sep 31; 22(9):1425-9. PubMed ID: 26138051
    [Abstract] [Full Text] [Related]

  • 20. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    Haque W, Teh C, Butler EB, Teh BS.
    J Neurooncol; 2022 Mar 31; 157(1):137-146. PubMed ID: 35103907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.